DMAC · DiaMedica Therapeutics Inc.
Market Cap
$364.00M
Shares
53.93M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$500K
FY2018
Net Income
-$32.77M
-34%
FY2025
Operating Margin
-1352.2%
FY2018
Operating Cash Flow
-$29.06M
-31.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | $500K | — | |
| $29.28M | $24.61M | $19.06M | $13.11M | $7.84M | $8.77M | $8.21M | $7.9M | $4.52M | $3.21M | |
| $9.95M | $9.78M | $7.62M | $8.16M | $6.16M | $4.88M | $4.49M | $3.69M | $2.74M | $1.31M | |
| — | $34.4M | $26.68M | $21.27M | $14M | $13.65M | $12.7M | $11.59M | $7.26M | $4.52M | |
| -$39.23M | -$34.4M | -$26.68M | -$21.27M | -$14M | -$13.65M | -$12.7M | -$11.59M | -$6.76M | -$4.52M | |
| — | — | — | — | — | — | — | — | -1352.2% | — | |
| $1.7M | $1.67M | $2.3M | $1.95M | — | — | — | — | — | — | |
| $1.72M | $1.66M | $2.27M | $1.93M | $353K | $82K | $434K | $975K | $1.11M | $259K | |
| -$37.51M | -$32.74M | -$24.41M | -$19.34M | -$13.65M | -$13.56M | -$12.27M | -$10.62M | -$5.65M | -$4.26M | |
| $30K | $28K | $30K | $43K | $28K | $28K | $27K | $31K | $80K | — | |
| -$37.54M | -$32.77M | -$24.44M | -$19.38M | -$13.68M | -$13.59M | -$12.29M | -$10.65M | -$5.73M | -$4.26M | |
| — | — | — | — | — | — | — | — | -1146.8% | — | |
| -$37.56M | -$32.74M | -$24.43M | -$19.3M | -$13.7M | -$13.64M | -$12.3M | -$10.65M | -$5.73M | — | |
| USD/shares | -$0.72 | -$0.70 | -$0.60 | -$0.60 | -$0.52 | -$0.65 | — | — | — | — |
| shares | — | 46.98M | 40.4M | 32.57M | 26.44M | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M |
| shares | — | — | — | — | — | 20.77M | 15.68M | 11.99M | 7.74M | 5.94M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 7.16×
EV/EBIT
—
Peer median 10.22×
P/E (TTM)
—
Peer median 13.19×
Peer medians compare against the 317 similar-size Biotechnology companies (of 537 listed).